Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Has Average Price Target of $21.00 According to Brokerages

Key Points

• Analysts maintain a bullish outlook: Amneal Pharmaceuticals has a consensus “Moderate Buy” rating, with nine buys and one sell among 10 analysts. The average 12-month price target is $21.00, compared with the stock’s reported opening price of $19.84.
• Amneal reported quarterly EPS of $0.30, exceeding the $0.24 consensus estimate, on revenue of $796.2 million. Analysts expect approximately $0.95 EPS for the current fiscal year, while management’s FY 2026 guidance is $0.96–$1.06 EPS.
• Insiders have been selling shares: Executives and directors sold 413,016 shares worth about $7.2 million over the past 90 days, although institutional investors own 31.82% of the company and several major funds recently increased their positions.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $21.00.

A number of analysts recently commented on AMRX shares. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. Barclays lifted their target price on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an "overweight" rating in a report on Thursday, September 17th. Leerink Partners began coverage on Amneal Pharmaceuticals in a research note on Wednesday, September 9th. They issued an "outperform" rating and a $23.00 target price for the company. UBS Group reissued a "buy" rating on shares of Amneal Pharmaceuticals in a research note on Thursday, October 1st. Finally, The Goldman Sachs Group restated a "buy" rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st.

Amneal Pharmaceuticals Trading Up 2.5%

AMRX stock opened at $19.84 on Wednesday. The business has a fifty day moving average price of $18.63 and a 200 day moving average price of $16.31. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. Amneal Pharmaceuticals has a fifty-two week low of $9.99 and a fifty-two week high of $21.17. The stock has a market capitalization of $6.34 billion, a price-to-earnings ratio of 40.49, a P/E/G ratio of 2.27 and a beta of 1.22.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The firm had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Analysts expect that Amneal Pharmaceuticals will post 0.95 EPS for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 210,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the transaction, the executive vice president directly owned 35,171 shares in the company, valued at $611,975.40. This trade represents a 85.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director John Kiely sold 50,000 shares of the business's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the transaction, the director owned 210,252 shares in the company, valued at approximately $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AMRX. Dimensional Fund Advisors LP boosted its position in Amneal Pharmaceuticals by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company's stock worth $70,723,000 after purchasing an additional 81,546 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Amneal Pharmaceuticals by 72.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company's stock valued at $32,405,000 after purchasing an additional 1,069,400 shares during the period. Congress Asset Management Co. raised its position in shares of Amneal Pharmaceuticals by 94.7% in the third quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company's stock valued at $30,701,000 after purchasing an additional 741,577 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at approximately $17,573,000. Finally, Principal Financial Group Inc. lifted its stake in shares of Amneal Pharmaceuticals by 527.9% during the 1st quarter. Principal Financial Group Inc. now owns 972,529 shares of the company's stock valued at $12,089,000 after buying an additional 817,652 shares in the last quarter. 31.82% of the stock is owned by institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company's generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.